Arkolith/Insider Trading/IKT/Form 4/A

Cabell Christopher

President & Head of R&DInhibikase Therapeutics, Inc. (IKT) · full profile →Form 4/A · filed Jul 2, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 21, 2025Grant(A)1.1M—$01.1M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0000950170-25-093445) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML